Durvalumab is a targeted cancer therapy, and its cost can be substantial, as is common with many advanced biologic drugs. The price of durvalumab can vary depending on factors such as dosage, treatment duration, and geographic location. Patient assistance programs and insurance coverage play a significant role in determining out-of-pocket expenses for individuals.
What is Durvalumab Used For?
Durvalumab, marketed as Imfinzi, is an immunotherapy medication used to treat certain types of cancer. It is an antibody that targets the PD-L1 protein on cancer cells and immune cells. By blocking this interaction, durvalumab helps the body's immune system recognize and attack cancer cells. It is approved for the treatment of:
* Locally advanced or metastatic urothelial carcinoma (bladder cancer) that has progressed during or after platinum-based chemotherapy [1].
* Locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed after chemoradiation therapy [1].
How Much Does Durvalumab Treatment Cost?
The list price for durvalumab can be high, often running into thousands of dollars per treatment cycle. For example, a typical monthly infusion of durvalumab might cost an estimated $7,000 to $10,000 or more, depending on the specific indication and formulation [2]. These figures represent the wholesale acquisition cost and do not account for discounts, rebates, or the costs incurred by healthcare providers for administration [2]. The total cost of treatment over the entire course of therapy can therefore amount to tens of thousands of dollars.
Are There Patient Assistance Programs for Durvalumab?
Pharmaceutical companies often provide patient assistance programs (PAPs) for their high-cost medications. AstraZeneca, the manufacturer of durvalumab, likely offers such programs to help eligible patients afford their treatment [3]. These programs can include co-pay assistance for commercially insured patients or provide the medication at no cost to uninsured or underinsured patients who meet specific financial criteria [3]. Patients and their healthcare providers can typically find information about these programs on the manufacturer's website or by contacting their patient support services.
How Does Insurance Cover Durvalumab?
Insurance coverage for durvalumab varies widely. Most insurance plans, including Medicare and private health insurance, will cover durvalumab if it is deemed medically necessary and prescribed for an FDA-approved indication [1, 3]. However, patients may still face significant out-of-pocket costs in the form of deductibles, co-payments, and co-insurance. The specific amount a patient pays depends on their individual insurance plan's formulary, benefit design, and whether they have met their plan's annual out-of-pocket maximum [3]. It is advisable for patients to confirm their coverage details with their insurance provider before starting treatment.
When Does Durvalumab Patent Exclusivity Expire?
Understanding the patent exclusivity of a drug is crucial for anticipating potential market changes, such as the introduction of generics or biosimilars. Information regarding durvalumab's patent landscape can be found through specialized resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, including expiry dates and potential challenges, which can influence the availability and cost of treatments in the future [4]. Specific patent expiry dates for durvalumab would require consulting such databases.
What Are the Side Effects of Durvalumab?
Like all medications, durvalumab can cause side effects. Common side effects may include fatigue, rash, diarrhea, nausea, and musculoskeletal pain [1]. More serious side effects can occur, often related to the immune system (immune-mediated adverse reactions) affecting organs such as the lungs, intestines, liver, and endocrine glands [1]. Patients should discuss potential side effects and their management strategies with their healthcare provider.
Who Manufactures Durvalumab?
Durvalumab is manufactured by AstraZeneca [1].
---
Sources:
[1] U.S. Food & Drug Administration. (n.d.). Imfinzi Prescribing Information. Retrieved from https://www.fda.gov/ (Note: Direct link to specific prescribing information may change; users should search the FDA site for "Imfinzi Prescribing Information")
[2] (General knowledge based on industry pricing for similar biologics. Specific, up-to-date pricing is best obtained from drug databases or by contacting manufacturers directly.)
[3] AstraZeneca. (n.d.). Patient Support Programs. Retrieved from https://www.astrazeneca.com/ (Note: Specific program details and links may vary; users should navigate to the patient support section of the AstraZeneca website.)
[4] DrugPatentWatch.com. (n.d.). Durvalumab. Retrieved from https://drugpatentwatch.com/